Procedures and variables
cough, Cough
BLOOD
The primary variable for the assessment of efficacy was Cough frequency was monitored in both treatment periods over 24 h before treatment (Day -1) and on the last treatment day of each dose step. The overall and awake mean cough frequency was determined for each 24 h period. At screening and at the end of each 24-h cough monitoring period, the participants completed the cough severity VAS; and prior to and at the end of each of the two treatment periods, they completed the LCQ.Primary variables for the assessment of safety and tolerability were the frequency and severity of treatment-emergent AEs (observed AEs, mentioned upon open questioning, and spontaneously reported AEs). Further safety assessments included standard clinical laboratory tests, vital signs, electrocardiograms, and physical examinations.Blood samples to determine filapixant concentrations in plasma were taken at the time points indicated in Fig. 